AEVEX Corp.
AVEX
$11.60
+0.35%
AEVEX Corp. is a defense technology company that designs and delivers next-generation navigation and autonomy systems, uncrewed aerial and surface vehicles, precision strike systems, and full-spectrum airborne ISR solutions, selling primarily to agencies within the U.S. Department of War, Special Operations Forces, the Intelligence Community, and allied international partners. As a recent NYSE entrant (listed April 2026) with a roughly $1.7 billion market capitalization, AEVEX positions itself as a pure-play defense-tech disruptor rather than a legacy prime contractor, competing on speed of delivery and attritable, software-enabled hardware tailored to the modern battlespace. The investor narrative is dominated by the post-IPO boom-and-bust cycle: shares rocketed on debut amid intense institutional demand for drone and ISR exposure tied to geopolitical flashpoints, but have since collapsed as enthusiasm cooled and the company's thin profitability and lumpy quarterly results came under scrutiny. Coverage from RBC, Piper Sandler, Needham, and J.P. Morgan has clustered around the story, with the debate now centered on whether AEVEX can convert its backlog of uncrewed-systems demand into durable, margin-accretive revenue or whether the IPO pop was a liquidity event disconnected from fundamentals.…
AVEX
AEVEX Corp.
$11.60
Related headlines
Investment Opinion: Should I buy AVEX Today?
Rating: Hold with a speculative-growth tilt. The core thesis is that AVEX is a genuine 99.53% year-over-year revenue grower trading at just 8.7x consensus forward EPS of $1.335, but the trailing record — a 1.15% Q2 net margin, 23.61% gross margin, and -0.20% trailing net margin — has not yet earned that forward math, and with no published average price target in the dataset the analyst upside cannot be precisely quantified even though roughly four of six ratings remain Buy-equivalent (RBC Outperform, Needham Buy, J.P. Morgan Overweight) against one Hold (Piper Sandler) and zero Sells. The stock at $11.56 sits roughly 22% of the way up its $9.26-$40.48 52-week range after a -77.12% max drawdown, so investors are being asked to underwrite an inflection, not a proven earnings stream.
Supporting evidence is mixed but leans toward asymmetric risk/reward. On the positive side: revenue of $201.79 million in Q2 2026 versus $101.13 million a year earlier (99.53% growth) with the multi-quarter arc rising from $121.24 million in Q3 2025 to above $200 million in each of the last two quarters; a current ratio of 5.47 and $216.13 million of cash; Q2 free cash flow of $16.95 million versus -$11.60 million in Q1; and a PS ratio of 3.99x that has compressed from 5.85x at Q2 2026 and 4.57x at Q1 2026 — the cheapest of its brief public life. Against that, gross margin fell to 23.61% from 26.07% in Q1, operating income dropped to $15.37 million (7.62% margin) from $29.62 million (13.67%), revenue slipped 6.9% sequentially, and EV/EBITDA of 54.09x on roughly $18.6 million of quarterly EBITDA is a dramatic outlier versus mid-teens sector norms — the 3.99x PS is also a roughly 30-100% premium to mature primes at 2-3x sales.
Three risks could invalidate the thesis: a second consecutive sub-24% gross-margin quarter, another sequential revenue decline confirming structural lumpiness, and a break below the $9.26 low with no historical floor beneath it. The rating would upgrade to Buy if gross margin reclaims the 26.07% Q1 level while revenue holds above $200 million (validating the 8.7x forward multiple), and would downgrade to Sell if gross margin prints below 23% again or if any of the four Buy-equivalent ratings is cut. On balance the stock is fairly valued to modestly undervalued relative to its own short history but still at a premium to the sector — a de-rating in progress rather than a completed one. This is an objective, data-driven assessment, not personalized financial advice.
Sign up to view all
AVEX 12-Month Price Forecast
AVEX presents a classic post-IPO de-rating where the multiple has collapsed (PS from 5.85x to 3.99x) faster than the revenue line, leaving an 8.7x forward EPS multiple that prices in almost no credit for the 99.53% growth. The problem is that trailing profitability does not yet support the forward math: Q2 net margin of 1.15%, gross margin of 23.61%, and trailing net margin of -0.20% mean the company is only marginally above breakeven, and EV/EBITDA of 54.09x is far too rich on cash-flow grounds alone. Sell-side conviction is intact — four Buy-equivalents, one Hold, no Sells, with no downgrades through the drawdown — but the absence of a published average target and the stock's seven-month trading history make that signal less reliable than for an established name. I would upgrade to bullish if Q3 gross margin reclaims 26% and revenue exceeds $216.69 million, and downgrade to bearish if gross margin prints below 23% again or the $9.26 low breaks on volume.
Wall Street consensus
Six analysts cover AEVEX, and the institutional ratings skew constructive: RBC Capital reiterated Outperform (October 22), Needham maintained Buy (August 13), and J.P. Morgan stayed Overweight (May 26), while Piper Sandler held Neutral, implying a consensus leaning bullish with roughly four Buy-equivalent ratings against one Hold and no explicit Sells. Consensus estimated EPS averages $1.335 (range $1.1337-$1.43149) on average estimated revenue of $1.35 billion (range $1.19-$1.42 billion), which at the current $11.56 price implies a forward earnings multiple of just 8.7x — strikingly cheap versus the 3.99x sales and 54x EV/EBITDA trailing metrics, and suggesting analysts expect a sharp profitability inflection that the trailing numbers do not yet reflect. A specific average price target is not available in the provided data, so implied upside cannot be precisely calculated, but the persistence of Outperform/Overweight ratings through a 55% drawdown signals that sell-side conviction has not broken even as the tape has. The target dispersion implied by the EPS range ($1.13 low to $1.43 high, a ~26% spread) is moderate rather than extreme, indicating reasonable but not ironclad conviction in the earnings recovery path. The high end of estimates likely assumes defense budget tailwinds, uncrewed-systems contract wins, and margin recovery toward the Q1 2026 gross margin of 26.07%, while the low end prices in continued contract lumpiness, gross-margin compression toward the 23.61% Q2 level, and the risk that the sequential revenue dip extends. Notably, no downgrades appear in the ratings history despite the collapse, which could reflect either genuine long-term conviction or lagging analyst response to a fast-moving post-IPO de-rating — a dynamic worth monitoring given the stock's limited trading history and the wide gap between sell-side optimism and market pricing.
Bulls vs Bears: AVEX Investment Factors
The bear case currently has stronger near-term evidence: margins are compressing (23.61% gross, 1.15% net), revenue fell sequentially, and the tape shows a -77.12% max drawdown with no confirmed higher low. The bull case rests on the forward math — 99.53% revenue growth and a 8.7x forward EPS multiple — which requires an inflection the trailing data has not yet delivered. The single most important tension is whether Q2's margin squeeze was a one-quarter contract-mix artifact or the start of a structural profitability problem; if gross margin reclaims the 26.07% Q1 level, the 8.7x forward multiple looks mispriced, but a second consecutive sub-24% quarter would validate the market's de-rating and likely break sell-side conviction.
Bullish
- Revenue nearly doubled year-over-year: Q2 2026 revenue of $201.79 million grew 99.53% versus $101.13 million in Q2 2025, a growth rate multiples of what legacy defense primes deliver. The multi-quarter arc from $121.24 million in Q3 2025 to above $200 million in each of the first two quarters of 2026 shows the demand curve is steep, not a one-off spike.
- Forward multiple of 8.7x on consensus EPS: At $11.56, consensus estimated EPS of $1.335 implies a forward earnings multiple of just 8.7x, versus a trailing PE of -97.5 and EV/EBITDA of 54.09x. The sell-side is explicitly modeling a sharp profitability inflection that the trailing numbers do not yet reflect, and the stock is priced as if that inflection never arrives.
- Sell-side conviction intact through 55% drawdown: Six analysts cover AVEX with roughly four Buy-equivalent ratings (RBC Outperform, Needham Buy, J.P. Morgan Overweight) against one Hold (Piper Sandler) and no Sells. No downgrades appear in the ratings history despite the -55.35% six-month decline, and the EPS estimate range of $1.1337-$1.43149 is a moderate ~26% spread rather than a sign of broken conviction.
- Balance sheet provides ample runway: A current ratio of 5.47 and $216.13 million of cash at period-end give AVEX substantial liquidity, while debt-to-equity of 0.43 is manageable. Q2 free cash flow of $16.95 million versus -$11.60 million in Q1 shows cash generation can turn positive as working capital normalizes.
Bearish
- Profitability is thin and deteriorating: Q2 2026 net income was just $2.33 million on a 1.15% net margin, down sharply from Q1's $20.93 million (9.66%) and Q4 2025's $12.40 million (7.88%). Trailing net margin of -0.20% and EPS of -$0.0005 mean the company is only marginally above breakeven, and ROE of -0.34% confirms capital is not earning a return.
- Gross margin compression and sub-prime levels: Gross margin fell to 23.61% in Q2 from 26.07% in Q1 and 24.37% in Q4 2025, and the current 21.78% metric is well below prime contractor norms. For a manufacturing-heavy hardware supplier, sub-25% gross margins leave little cushion if contract pricing tightens.
- Sequential revenue decline signals lumpiness: Q2 2026 revenue of $201.79 million slipped 6.9% sequentially from Q1's $216.69 million, and operating income fell to $15.37 million (7.62% margin) from $29.62 million (13.67%). Defense procurement is contract-timing dependent, and a single soft quarter can whipsaw sentiment for a newly public name.
- Severe downtrend with no established floor: The stock is down 55.35% over six months and sits at $11.56, roughly 22% of its 52-week range between $9.26 and $40.48, with a maximum drawdown of -77.12%. The 1-month relative strength of -17.66 versus SPY's -3.32 shows it is still bleeding far faster than the market, and a break below $9.26 opens fresh downside with no historical support.
AVEX Technical Analysis
AEVEX is locked in a severe, sustained downtrend, with the stock down 55.35% over the six-month window and sitting at just 11.56, roughly 22% of its 52-week range (the intraday high near 40.48 on May 28 versus the low around 9.26 on November 5). That positioning near the bottom of the range signals persistent distribution and a falling-knife profile rather than a value base, with a maximum drawdown of -77.12% underscoring how violent the de-rating has been since the post-IPO spike. The stock has given back essentially all of its debut gains and then some, leaving it in price-discovery mode with no established long-term support. Short-term momentum remains decisively negative but is showing tentative stabilization: the 1-month change of -20.98% and 3-month change of -47.81% confirm accelerating downside, yet the most recent session printed a +13.33% bounce off the 9.26 low, and the 1-month relative strength of -17.66 versus SPY's -3.32% shows the stock is still bleeding far faster than the market. The divergence between the +13.33% single-day surge and the -47.81% three-month collapse suggests a short-covering or oversold bounce rather than a trend reversal, especially given the absence of any confirmed higher low. With no beta reported, volatility must be inferred from the tape itself: a move from 40.48 to 9.26 in under six months implies realized volatility multiples of the broader market, demanding materially smaller position sizes. Key resistance sits at the 14.50-15.50 shelf (the October breakdown zone) and then the 20-22 region where the August rally failed; support is the 9.26 low, and a break below it would open fresh downside with no historical floor, while a reclaim of 15.50 would be the first credible sign of a bottoming process.
Beta
—
—
Max Drawdown
-77.1%
Largest decline past year
52-Week Range
—
Price range past year
Annual Return
—
Cumulative gain past year
| Period | AVEX Return | S&P 500 |
|---|---|---|
| 1m | -20.7% | -3.7% |
| 3m | -49.0% | -2.9% |
| 6m | -52.0% | +0.2% |
| 1y | — | +10.1% |
| ytd | — | +10.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
AVEX Fundamental Analysis
Revenue is growing explosively but unevenly: Q2 2026 revenue of $201.79 million represented 99.53% year-over-year growth versus $101.13 million in Q2 2025, though it slipped 6.9% sequentially from Q1 2026's $216.69 million. The multi-quarter arc is nonetheless impressive, with revenue climbing from $121.24 million in Q3 2025 to $157.31 million in Q4 2025 and then above $200 million in each of the first two quarters of 2026, and the product segment ($168.67 million) dwarfing services ($33.12 million) confirms AEVEX is a hardware-led uncrewed-systems story. The lumpiness and the sequential dip are the key caveat for the investment case, since defense procurement is contract-timing dependent and a single quarter's softness can whipsaw sentiment for a newly public name. Profitability is thin and volatile: Q2 2026 net income was just $2.33 million on a 1.15% net margin, a sharp step down from Q1 2026's $20.93 million (9.66% margin) and Q4 2025's $12.40 million (7.88% margin), while gross margin compressed to 23.61% from 26.07% in Q1 and 24.37% in Q4 2025. The Q2 squeeze came from operating income falling to $15.37 million (7.62% operating margin) from $29.62 million (13.67%) in Q1, compounded by $3.98 million of interest expense and a $6.22 million net other-expense drag, and the trailing net margin of -0.20% with EPS of -$0.0005 shows the company is only marginally above breakeven on a trailing basis. For an aerospace and defense hardware supplier, sub-25% gross margins are low relative to prime contractors, reflecting a manufacturing-heavy mix that leaves little cushion if contract pricing tightens. The balance sheet is the strongest part of the story: a current ratio of 5.47 and $216.13 million of cash at period-end provide ample liquidity, while debt-to-equity of 0.43 is manageable and Q2 free cash flow of $16.95 million (versus -$11.60 million in Q1) shows cash generation can turn positive as working capital normalizes. However, the Q1 receivables build of -$71.39 million and the Q2 debt repayment of -$160.34 million highlight heavy working-capital swings and balance-sheet restructuring, and ROE of -0.34% confirms capital is not yet earning a return; the company can fund near-term growth internally, but the negative price-to-cash-flow ratio of -17.68 signals cash flow quality remains inconsistent.
Quarterly Revenue
$201791000.0B
2026-06
Revenue YoY Growth
+99.5%
YoY Comparison
Gross Margin
23.6%
Latest Quarter
Free Cash Flow
N/A
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is AVEX Overvalued?
Because trailing net income is effectively zero (EPS of -$0.0005, trailing PE of -97.5), the PE ratio is not a meaningful anchor, so the price-to-sales ratio of 3.99x is the appropriate primary metric for this early-stage, high-growth defense name; the forward PE is unavailable (0), and with no forward earnings multiple to compare against, the market is implicitly pricing AEVEX on revenue and backlog rather than near-term profit. The EV/EBITDA of 54.09x is extremely rich and underscores that current EBITDA of roughly $18.6 million quarterly is far too small to justify a $1.7 billion enterprise value on cash-flow grounds alone. Against the broader aerospace and defense sector, where mature primes typically trade at 2-3x sales and mid-teens EV/EBITDA, AEVEX's 3.99x PS represents a premium of roughly 30-100% depending on the peer set, while its 54x EV/EBITDA is a dramatic outlier versus sector norms in the mid-teens. That premium can only be justified by the 99.53% revenue growth rate, which is multiples of what legacy defense contractors deliver, but the thin 23.61% gross margin and near-zero net margin mean the company is not yet earning the multiple on profitability. Historically, the stock's own valuation band has compressed violently: PS stood at 5.85x at Q2 2026 and 4.57x at Q1 2026, so the current 3.99x is near the low end of its short public history, and the PB ratio has swung from 3.18x in Q1 to 7.01x now as equity was rebuilt post-IPO. The compression from ~5.8x to ~4.0x sales alongside a 55% price decline suggests the market is de-rating the growth story rather than abandoning it, leaving the stock at the cheaper end of its own range but still at a premium to the sector.
PE
-97.5x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
37.1x
Industry PE ~37.1x*
EV/EBITDA
54.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are concentrated in the margin line and earnings volatility. Q2 2026 net income of $2.33 million on a 1.15% net margin followed $20.93 million (9.66%) in Q1, a swing that shows how little cushion exists beneath a 23.61% gross margin, and trailing net margin of -0.20% with ROE of -0.34% means the business is not yet earning its cost of capital. Interest expense of $3.98 million plus a $6.22 million net other-expense drag consumed most of Q2's $15.37 million operating income, and the -6.9% sequential revenue decline from $216.69 million to $201.79 million confirms contract-timing lumpiness. Cash flow quality is also uneven: the -17.68 price-to-cash-flow ratio, a Q1 receivables build of -$71.39 million, and a -$160.34 million Q2 debt repayment show heavy working-capital and balance-sheet swings despite $216.13 million of cash and a 5.47 current ratio. Market and competitive risks center on valuation compression. At 3.99x sales and 54.09x EV/EBITDA, AVEX trades at roughly a 30-100% premium to aerospace and defense primes on sales and a dramatic outlier on EBITDA versus mid-teens sector norms, a premium that can only be defended by 99.53% growth. The stock has already de-rated from 5.85x sales at Q2 2026 to 3.99x, and with no reported beta, the realized volatility implied by a move from $40.48 to $9.26 in under six months demands materially smaller position sizes. Competitive pressure from legacy primes and other defense-tech entrants, plus dependence on DoW, SOF, and IC budget cycles, adds sector-rotation risk to a name with only seven months of public trading history. The worst-case scenario is a second consecutive quarter of sub-24% gross margin combined with another sequential revenue decline, which would likely trigger downgrades from the current four Buy-equivalent ratings and remove the 8.7x forward EPS anchor. In that chain, the stock retests and breaks the $9.26 low set on November 5, and with no historical floor below it, a move toward the $7-8 range is plausible — roughly -30% to -40% from the current $11.56. A repeat of the -77.12% max drawdown from the $40.48 peak would imply a far deeper outcome, so position sizing should assume at least a -35% downside to the 52-week low as the realistic adverse case.
FAQ
The most severe risk is financial: profitability is thin and deteriorating, with Q2 net income of $2.33 million on a 1.15% net margin versus $20.93 million (9.66%) in Q1, and gross margin compressing to 23.61% from 26.07% — a second sub-24% quarter would likely break the forward-EPS anchor. Second is company-specific execution risk: revenue fell 6.9% sequentially to $201.79 million from $216.69 million, and defense procurement timing means a single soft quarter can whipsaw a newly public name with only seven months of trading history. Third is valuation and market risk: at 54.09x EV/EBITDA and 3.99x sales, AVEX trades at a premium to primes, and with no reported beta the realized volatility — a move from $40.48 to $9.26 in under six months — demands materially smaller position sizes. Fourth is technical and sentiment risk: the stock is down 55.35% over six months with a -77.12% max drawdown, and a break below the $9.26 low opens fresh downside with no historical support, while the -17.66 one-month relative strength versus SPY's -3.32 shows it is still bleeding far faster than the market.
The base case carries 55% probability with a $11-16 target range, assuming revenue stabilizes in the $190-220 million quarterly band, gross margin holds between 23% and 26%, and the 8.7x forward EPS anchor survives without a decisive re-rating. The bull case at 20% probability targets $22-30, requiring gross margin to recover toward the 26.07% Q1 level, revenue to re-accelerate past $216.69 million, and the multiple to re-rate toward defense-tech peers — roughly in line with the August 2026 $22.75 rally high. The bear case at 25% probability targets $7-9.26, triggered by a second consecutive sub-24% gross margin quarter plus another sequential revenue decline, which would break the $9.26 November low and open the $7-8 range. The base case is most likely because the balance sheet ($216.13 million cash, 5.47 current ratio) and intact sell-side conviction (four Buy-equivalents, one Hold, zero Sells) provide time for the margin story to resolve, but the 25% bear probability is unusually high for a base-case-dominant forecast, reflecting the genuine risk that the profitability inflection never arrives.
The answer depends on which metric you anchor to, and that divergence is the heart of the debate. On trailing numbers the stock looks expensive: the trailing PE is -97.5 because EPS is -$0.0005, EV/EBITDA is 54.09x on roughly $18.6 million of quarterly EBITDA, and the price-to-cash-flow ratio is -17.68. On forward numbers it looks cheap: 8.7x consensus EPS of $1.335, and 3.99x sales, which has compressed from 5.85x at Q2 2026 and 4.57x at Q1 2026 — the low end of its brief public history. Against mature aerospace and defense primes at 2-3x sales and mid-teens EV/EBITDA, however, the 3.99x PS is still a roughly 30-100% premium and the 54x EV/EBITDA is a dramatic outlier. The market is therefore paying a premium to the sector but a discount to the company's own history, implying it expects the 99.53% growth to continue but is no longer willing to pay peak multiples for it — a de-rating in progress rather than a completed one.
The risk/reward is asymmetric but unproven. On the positive side, AVEX trades at $11.56 against consensus forward EPS of $1.335, an 8.7x forward multiple for a company that grew revenue 99.53% year-over-year to $201.79 million, with $216.13 million of cash and a 5.47 current ratio. On the negative side, the trailing record shows a 1.15% Q2 net margin, 23.61% gross margin, and -0.20% trailing net margin, meaning the forward earnings the multiple discounts have not yet appeared, and the stock has already fallen 55.35% over six months with a -77.12% max drawdown. The biggest downside risk is a break below the $9.26 November low, which would imply roughly -20% from here with no historical floor beneath it. It is a reasonable buy only for risk-tolerant investors who size the position for a -35% adverse case and who are willing to wait for Q3 gross margin to confirm the inflection; for conservative or income-oriented investors, it is not a good buy at this stage.
AVEX is best suited to a long-term holding period of at least 18-24 months, and only for investors comfortable with speculative growth exposure. The company is early-stage — listed April 17, 2026, with a seven-month trading history — and its earnings visibility is low: quarterly revenue has swung from $121.24 million to $216.69 million and back to $201.79 million, and net margin has ranged from -11.71% in Q2 2025 to 9.66% in Q1 2026. The dividend yield of 0.29% is negligible and the payout ratio of -5.90 reflects negative earnings, so there is no income case for holding. Volatility is extreme — a -77.12% max drawdown from the $40.48 May peak to the $9.26 November low — which makes short-term trading a momentum bet against a falling knife rather than an investment strategy. A concrete minimum holding period of 18-24 months allows time for two to three more quarterly reports to confirm whether gross margin can sustainably hold above 26% and whether the 8.7x forward EPS materializes; shorter horizons should be treated as trading positions with tight risk limits around the $9.26 support.